ARTICANZ - Beta (ver 0.91)

Annotated Registry of Trials in Cancer, Australia and New Zealand Ed. - Results - target/ALK-inhibitor-second-generation

ARTICANZ (Annotated Registry of Trials in Cancer, Australia/NZ Edition; ARTificial Intelligence-enhanced CANcer trial information database) provides information about cancer drug trials in Australia and New Zealand as a free, open-information platform. Please note the following:

Data Accuracy: While ARTICANZ strives to maintain accurate and up-to-date information through regular weekly updates and specialist review, we cannot guarantee the complete accuracy, reliability, or timeliness of all data. Information may change between updates.
Not Medical Advice: The information provided by ARTICANZ is for informational purposes only and should not be considered medical advice. All clinical decisions should be made in consultation with qualified healthcare professionals.
No Warranty: ARTICANZ is provided "as is" without any warranties, expressed or implied. We disclaim all liability for any damages arising from the use of or inability to use this platform.
External Links: ARTICANZ may contain links to external websites. We are not responsible for the content or privacy practices of these sites.

By using ARTICANZ, you acknowledge that you have read and understood this disclaimer.

The ARTICANZ platform and its contents are made available under the Creative Commons Attribution 4.0 International License (CC BY 4.0).

Users are free to:

Share — copy and redistribute the data in any medium or format
Adapt — remix, transform, and build upon the data
Use the data for any purpose, including commercial use

Under the following terms:

Attribution — You must give appropriate credit to ARTICANZ, provide a link to the license, and indicate if changes were made
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits

Platform developed and currently maintained by Dr. Frank Lin and the ARTICANZ team.

ALK	100%
RET	100%
ROS1	50%
PD-1/PD-L1	25%
PD-L1	25%
TRK	25%
AXL	25%
BCR-ABL1	25%
CDK4	25%
CDK6	25%
CRAF	25%
EGFR	25%
ERBB2	25%
FGFR1	25%
FGFR1/2/3	25%
FGFR2	25%
FGFR3	25%
FGFR4	25%
FLT3	25%
HDAC	25%
IGF1R	25%
KIT	25%
MEK	25%
MET	25%
PARP	25%
PDGFR	25%
PDGFRA	25%
RAF	25%
SRC	25%
VEGFR	25%
VEGFR2	25%
YES1	25%
mTOR	25%
mTORC1	25%
proteasome	25%

ARTICANZ - Beta (ver 0.91)

Search results

target/ALK-inhibitor-second-generation

Filters